🏛️ Verified NIH Record • Updated 2025-04-29

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency (NCT06046820)

The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Inozyme Pharma

🩺 Plain-English Summary (8th-Grade Level)

The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.

Who can join: Review the eligibility criteria below.

Location: Children's Hospital of Colorado — Aurora, Colorado

Age range: 1 Year to 12 Years

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (15 Sites)

  • Children's Hospital of Colorado — Aurora, Colorado
  • Ann & Robert H. Lurie Children's Hospital — Chicago, Illinois
  • Boston Children's Hospital — Boston, Massachusetts
  • Nationwide Children's Hospital — Columbus, Ohio
  • The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
  • Cook Children's Medical Center — Fort Worth, Texas
  • Queensland Children's Hospital — South Brisbane,
  • Centre Hospitalier Universitaire (CHU) Sainte-Justine — Montreal,
  • Hôpital Bicêtre, Service d'endocrinologie et diabète de l'enfant (Childhood Endocrinology and Diabetes Department) — Le Kremlin-Bicêtre,
  • King Faisal Specialist Hospital and Research Centre — Riyadh,
  • Hospital San Joan de Deu — Barcelona,
  • Umraniye Training and Research Hospital — Istanbul,
  • Cukurova Universitesi Tip Fakultesi — Sarıçam,
  • Al Jalila Children's Specialty Hospital — Dubai,
  • Royal Manchester Children's Hospital — Manchester,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗